Weight loss drugs have taken the pharmaceutical and medical communities by storm. Not only are the companies behind the medications struggling to keep up with global demand, but reports are emergin...

Eli Lilly's shares have soared more than 50% this year to about $900. This level may discourage some investors from hitting the buy button.

Louise Chen, Cantor Fitzgerald analyst, joins CNBC's 'Squawk Box' to discuss Eli Lilly's surge over the past year, manufacturing, and more.

Eli Lilly is investing billions into additional capacity to ensure it's able to meet soaring demand for its products. Demand could accelerate even further if Mounjaro and Zepbound obtain approval f...

Eli Lilly said on Tuesday it will collaborate with OpenAI to leverage its generative AI to develop antimicrobials that can be used to treat drug-resistant bacteria.

INDIANAPOLIS , June 24, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2024 of $1.30 per share on outstanding comm...

Lilly's Alzheimer's disease drug donanemab could receive FDA approval by year-end. Donanemab would likely be covered by Medicare if approved.

U.S. drugmaker Eli Lilly on Thursday said it was suing six more U.S. medical spas, wellness centers and other entities for selling products claiming to contain tirzepatide, the active ingredient in...

On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.

Eli Lilly is ramping up manufacturing to meet the soaring demand for its innovative medicines.

Madrigal Pharmaceuticals is the only company with an approved drug for MASH. Eli Lilly's latest clinical trial data shows that its candidate may perform even better.

Eli Lilly is developing Mounjaro (tirzepatide) for treating non-alcoholic steatohepatitis. The drugmaker reported positive phase 2 results along those lines earlier this year.

Eli Lilly's potential Alzheimer's treatment looks closer than ever to approval. It could be a nice addition to the pharmaceutical giant's already-deep portfolio.

The use of artificial intelligence across biopharma and life science tools and services is developing quickly. Will A.I. become a major disruptive technology in healthcare with the potential to sig...

The pharmaceutical sector is one that has gone from decades of heavy investment, high growth, and consolidation to a maturing space with a few key players that have more recently provided much more...